3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
154
Brain Neoplasms
73
Glioma
69
Central Nervous System Neoplasms
50
Gliosarcoma
46
Astrocytoma
37
Melanoma
36
Oligodendroglioma
29
Neuroblastoma
17
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
11
Sarcoma, Ewing
10
Sarcoma
10
Neoplasms
10
Medulloblastoma
10
Recurrence
9
Neuroendocrine Tumors
9
Lymphoma
8
Ependymoma
8
Breast Neoplasms
8
Small Cell Lung Carcinoma
7
Rhabdomyosarcoma
7
Diffuse Intrinsic Pontine Glioma
7
Colorectal Neoplasms
7
Carcinoma, Neuroendocrine
6
Adenoma, Islet Cell
6
Uveal Melanoma
5
Spinal Cord Neoplasms
5
Pheochromocytoma
5
Interventions
Cyclophosphamide
116
fludarabine phosphate
101
Busulfan
83
Tacrolimus
75
fludarabine
73
Mycophenolic Acid
71
Whole-Body Irradiation
65
Peripheral Blood Stem Cell Transplantation
59
Antilymphocyte Serum
58
Cyclosporine
53
Azacitidine
53
Melphalan
50
Cytarabine
47
Filgrastim
43
Methotrexate
41
Granulocyte Colony-Stimulating Factor
34
Decitabine
33
Radiotherapy
28
Thiotepa
27
Cord Blood Stem Cell Transplantation
27
thymoglobulin
26
Stem Cell Transplantation
26
Clofarabine
22
Methylprednisolone
20
Sirolimus
19
Alemtuzumab
16
venetoclax
15
Specimen Handling
14
sargramostim
13
Etoposide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Myelodysplastic Syndromes
×
Temozolomide
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts